Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,294,680
  • Shares Outstanding, K 201,483
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.99
  • Price/Sales 5.33
  • Price/Cash Flow 12.50
  • Price/Book 4.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 6.72
  • Number of Estimates 27
  • High Estimate 7.65
  • Low Estimate 5.96
  • Prior Year 5.26
  • Growth Rate Est. (year over year) +27.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
278.46 +21.10%
on 12/24/18
344.00 -1.97%
on 01/23/19
+56.62 (+20.18%)
since 12/21/18
3-Month
278.46 +21.10%
on 12/24/18
344.00 -1.97%
on 01/23/19
+21.07 (+6.66%)
since 10/23/18
52-Week
249.17 +35.34%
on 04/24/18
388.67 -13.24%
on 07/25/18
-9.53 (-2.75%)
since 01/23/18

Most Recent Stories

More News
Shares of Biogen Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (BIIB , CARA , LOXO , CELG , GILD )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CARA : 15.02 (-2.09%)
LOXO : 233.70 (-0.03%)
BIIB : 337.22 (-0.51%)
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips

The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips

SYY : 62.89 (+0.37%)
SCHW : 47.32 (-0.32%)
PFE : 42.16 (-0.26%)
PHG : 36.20 (+1.46%)
BIIB : 337.22 (-0.51%)
Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?

While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.

CELG : 86.50 (+0.58%)
RHHBY : 32.4800 (+0.85%)
AMGN : 201.56 (-0.21%)
BIIB : 337.22 (-0.51%)
Top Stock Reports for Pfizer, Biogen & Schwab

Top Stock Reports for Pfizer, Biogen & Schwab

SYY : 62.89 (+0.37%)
SCHW : 47.32 (-0.32%)
CSX : 65.08 (-1.14%)
PHG : 36.20 (+1.46%)
PFE : 42.16 (-0.26%)
BIIB : 337.22 (-0.51%)
Shares of BIIB Up 8.7% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Biogen Inc (NASDAQ:BIIB) on January 3rd, 2019 at $311.31. In approximately 2 weeks, Biogen Inc has returned 8.68% as of today's recent price of $338.34.

BIIB : 337.22 (-0.51%)
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BIIB : 337.22 (-0.51%)
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

CELG : 86.50 (+0.58%)
ALNY : 80.01 (-0.81%)
LOXO : 233.70 (-0.03%)
SAGE : 130.74 (-4.77%)
GILD : 68.25 (-0.44%)
REGN : 401.21 (-0.87%)
BIIB : 337.22 (-0.51%)
Biogen Inks Two Deals to Make Drugs for Neurological Diseases

Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.

ACIU : 10.25 (-5.36%)
LLY : 118.79 (+1.45%)
PFE : 42.16 (-0.26%)
BIIB : 337.22 (-0.51%)
Biogen Begins Improved Dosing Regimen on Tysabri in Phase III

Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.

GHDX : 70.90 (-0.14%)
RHHBY : 32.4800 (+0.85%)
ALKS : 32.44 (-1.85%)
BIIB : 337.22 (-0.51%)
Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

- C4T's targeted protein degradation platform provides a novel approach to neuroscience drug discovery and development, complementing Biogen's broader research and development efforts across multiple modalities...

BIIB : 337.22 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 344.81
1st Resistance Point 341.89
Last Price 337.22
1st Support Level 334.85
2nd Support Level 330.73

See More

52-Week High 388.67
Last Price 337.22
Fibonacci 61.8% 335.38
Fibonacci 50% 318.92
Fibonacci 38.2% 302.46
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar